121 related articles for article (PubMed ID: 30010037)
1. Hypermethylated LATS2 gene with decreased expression in female breast cancer: A case control study from North India.
Sadaf ; Habib M; Khan MA; Najm MZ; Mallick MN; Sunita K; Shukla NK; Deo SVS; Husain SA
Gene; 2018 Nov; 676():156-163. PubMed ID: 30010037
[TBL] [Abstract][Full Text] [Related]
2. Promoter Hypermethylation of LATS2 Gene in Oral Squamous Cell Carcinoma (OSCC) Among North Indian Population.
Goel H; Singhal S; Mathur R; Syeda S; Gupta RK; Kumar A; Shrivastava A; Jha AK
Asian Pac J Cancer Prev; 2020 May; 21(5):1283-1287. PubMed ID: 32458634
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
4. [Expression of large tumor suppressor homolog 2 gene and its promotor methylation in oral squamous cell carcinoma].
Yue ZW; Liu JZ
Zhonghua Kou Qiang Yi Xue Za Zhi; 2017 Sep; 52(9):569-573. PubMed ID: 29972924
[No Abstract] [Full Text] [Related]
5. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
[TBL] [Abstract][Full Text] [Related]
6. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
[TBL] [Abstract][Full Text] [Related]
7. Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas.
Levallet G; Creveuil C; Bekaert L; Péres E; Planchard G; Lecot-Cotigny S; Guillamo JS; Emery E; Zalcman G; Lechapt-Zalcman E
J Mol Diagn; 2019 Jul; 21(4):695-704. PubMed ID: 31055025
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of MGMT in correlation with aberrant DNA methylation in esophageal cancer patients from North India.
Rehman AU; Saikia S; Iqbal MA; Ahmad I; Sadaf ; Anees A; Aravinda PS; Mishra PK; Hedau S; Saluja SS; Medhi S; Husain SA
Tumour Biol; 2017 Jun; 39(6):1010428317705770. PubMed ID: 28621225
[TBL] [Abstract][Full Text] [Related]
9. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.
Li W; Wang L; Katoh H; Liu R; Zheng P; Liu Y
Cancer Res; 2011 Mar; 71(6):2162-71. PubMed ID: 21278236
[TBL] [Abstract][Full Text] [Related]
10. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.
Malik SA; Khan MS; Dar M; Hussain MU; Shah MA; Shafi SM; Mudassar S
Pathol Oncol Res; 2018 Apr; 24(2):207-214. PubMed ID: 28434174
[TBL] [Abstract][Full Text] [Related]
11. LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis.
Zhang Y; Hu CF; Chen J; Yan LX; Zeng YX; Shao JY
BMC Cancer; 2010 Oct; 10():538. PubMed ID: 20932276
[TBL] [Abstract][Full Text] [Related]
12. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
[TBL] [Abstract][Full Text] [Related]
13. ECRG4 acts as a tumor suppressor gene frequently hypermethylated in human breast cancer.
Tang GY; Tang GJ; Yin L; Chao C; Zhou R; Ren GP; Chen JY; Zhang W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30918105
[TBL] [Abstract][Full Text] [Related]
14. Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer.
Zhao C; Chen J; Liu Y; Ju S; Wang G; Wang X
Bioengineered; 2021 Dec; 12(2):11648-11661. PubMed ID: 34699318
[TBL] [Abstract][Full Text] [Related]
15. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer.
Gupta V; Agarwal P; Deshpande P
Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma.
Jiang Z; Li X; Hu J; Zhou W; Jiang Y; Li G; Lu D
Neurosci Res; 2006 Dec; 56(4):450-8. PubMed ID: 17049657
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
18. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
19. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
